| Salah Najm, MD | |
|
823 Sw Mulvane St, Topeka, KS 66606-1764 | |
| (785) 354-9591 | |
| Not Available |
| Full Name | Salah Najm |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 19 Years |
| Location | 823 Sw Mulvane St, Topeka, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982868097 | NPI | - | NPPES |
| 068002169 | Other | KS | MEDICARE PTAN |
| 200962480A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 04-35618 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stormont Vail Hospital | Topeka, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cotton O'neil Clinic Revocable Trust | 5496659195 | 576 |
News Archive
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.
Connecticut House Majority Leader Christopher Donovan (D) on Tuesday asked Gov. Jodie Rell (R) to delay implementing a new health plan for uninsured adults because of concerns that it could disrupt care for children in low-income families, the Hartford Courant reports.
› Verified 2 days ago
| Entity Name | Cotton O'neil Clinic Revocable Trust |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811944457 PECOS PAC ID: 5496659195 Enrollment ID: O20031124000674 |
News Archive
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.
Connecticut House Majority Leader Christopher Donovan (D) on Tuesday asked Gov. Jodie Rell (R) to delay implementing a new health plan for uninsured adults because of concerns that it could disrupt care for children in low-income families, the Hartford Courant reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Salah Najm, MD 823 Sw Mulvane St, Topeka, KS 66606-1764 Ph: (785) 354-9591 | Salah Najm, MD 823 Sw Mulvane St, Topeka, KS 66606-1764 Ph: (785) 354-9591 |
News Archive
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.
Connecticut House Majority Leader Christopher Donovan (D) on Tuesday asked Gov. Jodie Rell (R) to delay implementing a new health plan for uninsured adults because of concerns that it could disrupt care for children in low-income families, the Hartford Courant reports.
› Verified 2 days ago
Dr. Jerry R. Majers, D.O. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2200 Sw Gage Blvd, Topeka, KS 66622 Phone: 785-350-3111 | |
James Patrick Birkbeck, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 929 Sw Mulvane St, Topeka, KS 66606 Phone: 785-270-4100 | |
Dr. Steven E Seals, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 929 Sw Mulvane St, Topeka, KS 66606 Phone: 785-270-4100 Fax: 785-270-4202 | |
John L Joliff, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 600 Sw College Ave, Topeka, KS 66606 Phone: 784-233-9643 Fax: 785-233-6821 | |
Amarinder Pal Singh, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1700 Sw 7th Street, Topeka, KS 66606 Phone: 785-295-8000 Fax: 785-231-5988 | |
Dr. Craig F Gernon, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 929 Sw Mulvane St, Topeka, KS 66606 Phone: 785-270-4100 Fax: 785-270-4177 | |
Bradley W Marples, Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 901 Sw Garfield Ave, Topeka, KS 66606 Phone: 785-354-9595 |